# CORRECTION Open Access



# Correction: Optimising AVATAR therapy for people who hear distressing voices: study protocol for the AVATAR2 multi-centre randomised controlled trial

Philippa Garety<sup>1,2</sup>, Clementine J. Edwards<sup>1,2\*</sup>, Thomas Ward<sup>1,2</sup>, Richard Emsley<sup>1</sup>, Mark Huckvale<sup>3</sup>, Paul McCrone<sup>4</sup>, Mar Rus-Calafell<sup>5</sup>, Miriam Fornells-Ambrojo<sup>3,6</sup>, Andrew Gumley<sup>7,8</sup>, Gillian Haddock<sup>9,10</sup>, Sandra Bucci<sup>9,10</sup>, Hamish McLeod<sup>7,8</sup>, Amy Hardy<sup>1,2</sup>, Emmanuelle Peters<sup>1,2</sup>, Inez Myin-Germeys<sup>11</sup> and Thomas Craig<sup>1,2</sup>

Correction: Trials 22, 366 (2021) https://doi.org/10.1186/s13063-021-05301-w

Following the publication of the original article [1], we were notified that the reference numbers provided in Table 1 were incorrect.

The original article can be found online at https://doi.org/10.1186/s13063-021-05301-w.

\*Correspondence:

Clementine J. Edwards

clementine.edwards@kcl.ac.uk

<sup>1</sup> Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK

<sup>2</sup> South London & Maudsley NHS Foundation Trust, London, UK

<sup>3</sup> University College London, London, UK

<sup>4</sup> University of Greenwich, London, UK

<sup>5</sup> Mental Health Research and Treatment Center, Faculty of Psychology, Ruhr-Universität Bochum, Bochum, Germany

<sup>6</sup> South London & Maudsley NHS Foundation Trust, London, UK

<sup>7</sup> University of Glasgow, Glasgow, UK

<sup>8</sup> NHS Greater Glasgow & Clyde, Glasgow, UK

<sup>9</sup> University of Manchester and the Manchester Academic Health Sciences Centre, Manchester, UK

<sup>10</sup> Greater Manchester Mental Health NHS Foundation Trust and the Manchester Academic Health Sciences Centre, Manchester, UK

<sup>11</sup> KU Leuven, Leuven, Belgium



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Garety et al. Trials (2024) 25:803 Page 2 of 3

# Originally published Table 1:

	Measure	Time- point <sup>a</sup>
Distress, frequency and severity of voices outcome measures	Psychotic Symptom Rating Scales – Auditory Hallucinations – a dimensional measure of hallucinations- [27]. Includes Distress dimension (primary outcome), Total score (secondary outcome), and Frequency dimension (secondary outcome) [28]. Hallucinations Remission Score	Screening, 1, 2, 3
Other voices outcome measures	Beliefs about Voices Revised (BAVQ-R) [30] Voices acceptance and action scale (VAAS) [31] First item (power) from the Voice Power Differential Scale [32]	1, 2, 3
Experience sampling methodology	AVATAR2 ESM Questionnaire [33]	1,2,3
	AVATAR2 ESM Debrief Questionnaire e.g. [34]	1,2,3
Other secondary outcome measures	Mood: Beck Depression Inventory-II [35]	1, 2, 3
	Anxiety: Depression Anxiety and Stress Scales (DASS-21) [36]	1,2,3
	Quality of Life: Warwick-Edinburgh Mental Well-being Scale [37]	1, 2, 3
	Delusions: Psychotic Symptoms Rating Scale (PSYRATS-DEL) [27]	1, 2, 3
	Service User Led Outcome Measure: Choice of Outcome in CBT for Psychosis (CHOICE) Short Form [38]	1,2,3
	Trauma related symptoms – International Trauma Questionnaire (ITQ) [39]	1, 2
Health economic outcome measures	Service use and costs: costs of the intervention (based on staff time, overheads and equipment) and the costs of other key health and social care services calculated using the [40].	1, 2, 3
	EQ-5D-5L [41] to measure QALYs	1, 2, 3
Baseline clinical characteristics	Voice Characterisation Checklist: Assesses the complexity in characterisation of the dominant voice. Rated as more vs. less highly characterised based on presence/absence of ascribed identity (e.g. known, name), physical characteristics (e.g. age, gender, accent) and psychosocial characteristics (e.g. intentions, thoughts, relationships)-see [19]. Including two items from the Voice Phenomenology Interview [42].	1
	Fearful Attachment Style Item from Relationships Questionnaire [43].	1
	Patient perceived trauma-voice links - Trauma Voice Associations Questionnaire (TVAQ) [44].	1
	Trauma history - Mini-Trauma And Life Events (TALE) checklist [45]	1
	Clinical Assessment Interview for Negative Symptoms (CAINS) [46]	1
	Identification of positive symptoms – Initial items from the Schedules for Clinical Assessment in Neuropsychiatry (SCAN) 2.1 [47]	1
	Detailed assessment of positive symptoms - Scale for the Assessment of Positive Symptoms [48]	1
COMD-19 Impact	COVID-19 Context Questionnaire to assess individual circumstances during pandemic and change in voice experiences.	1, 2, 3

Garety et al. Trials (2024) 25:803 Page 3 of 3

## Corrected Table 1:

			teristics
	Measure	Time-point*	
Distress, Frequency and Severity of Voices Out- come Measures	Psychotic Symptom Rating Scales – Auditory Halluci- nations – a dimensional measure of hallucinations <sup>29</sup> . Includes Distress dimension (primary outcome), Total score (secondary outcome), and Frequency dimension (secondary outcome) <sup>30</sup> . Hallucinations Remission Score	Screening, 1, 2, 3	
Other Voices Outcome Measures	Beliefs about Voices Revised (BAVQ-R) <sup>32</sup> . Voices acceptance and action scale (VAAS) <sup>33</sup> . First item (power) from the Voice Power Differential Scale <sup>34</sup> .	1, 2, 3	
Experience Sampling Methodology	AVATAR2 ESM Questionnaire <sup>35</sup> .	1,2,3	
	AVATAR2 ESM Debrief Questionnaire <sup>36</sup> .	1,2,3	
Other Secondary Outcome Measures	Mood: Beck Depression Inventory-II <sup>37</sup> .	1, 2, 3	
	Anxiety: Depression Anxiety and Stress Scales (DASS-21) <sup>38</sup> .	1,2,3	
	Quality of Life: Warwick- Edinburgh Mental Well- being Scale <sup>39</sup> .	1, 2, 3	
	Delusions: Psychotic Symptoms Rating Scale (PSYRATS-DEL) <sup>29</sup> .	1, 2, 3	
	Service User Led Outcome Measure: Choice of Out- come in CBT for Psychosis (CHOICE) Short Form <sup>40</sup> .	1,2,3	Covid-19 Impact
	Trauma related symptoms – International Trauma Questionnaire (ITQ) <sup>41</sup> .	1, 2	
Health Economic Outcome Measures	Service use and costs: costs of the interven- tion (based on staff time, overheads and equipment) and the costs of other key health and social care ser- vices calculated using the <sup>42</sup> .	1, 2, 3	The origina
	EQ-5D-5L <sup>43</sup> to measure QALYs	1, 2, 3	<b>Reference</b> 1. Garety, et al. (

Baseline Clinical Charac-	Voice Characterisa-	1
eristics	tion Checklist: Assesses	
	the complexity in charac-	
	terisation of the dominant	
	voice. Rated as more vs.	
	less highly characterised	
	based on presence/absence	
	of ascribed identity (e.g.	
	known, name), physical	
	characteristics (e.g. age, gender, accent) and psy-	
	chosocial characteristics	
	(e.g. intentions, thoughts,	
	relationships)-see <sup>21</sup> .	
	Including two items	
	from the Voice Phenom-	
	enology Interview <sup>44</sup> .	
	Fearful Attachment Style	1
	Item from Relationships	
	Questionnaire <sup>45</sup> .	
	Patient perceived trauma-	1
	voice links - Trauma Voice	
	Associations Questionnaire	
	(TVAQ)	
	Trauma history - Mini-	1
	Trauma And Life Events	
	(TALE) checklist <sup>46</sup> .	
	Clinical Assessment	1
	Interview for Negative	
	Symptoms (CAINS) <sup>47.</sup>	
	Identification of positive	1
	symptoms – Initial items	
	from the Schedules for Clini-	
	cal Assessment in Neuropsy-	
	chiatry (SCAN) 2.1 <sup>48</sup> .	
	Detailed assessment	1
	of positive symptoms - Scale	
	for the Assessment of Positive Symptoms <sup>49</sup> .	
Cavid 10 loops at	* *	1 2 2
Covid-19 Impact	Covid-19 Context Question- naire to assess individual	1, 2, 3
	circumstances during pan-	
	demic and change in voice	
	experiences.	

### al article has been corrected.

ne: 29 November 2024

### Reference

Garety, et al. Optimising AVATAR therapy for people who hear distressing voices: study protocol for the AVATAR2 multi-centre randomised controlled trial. Trials. 2021;22:366. https://doi.org/10.1186/s13063-021-05301-w.